



Coverage of any medical intervention discussed in a WellFirst Health medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Measurement of Serum Levels and Antibodies (infliximab) and HUMIRA (adalimumab) MP9464

Covered Service: Yes

Prior Authorization Required: Yes

Additional Information: None

WellFirst Health Medical Policy:

- 1.0 Measurement of serum levels and antibodies for either of the following: infliximab and HUMIRA (adalimumab) **requires** prior authorization through the Health Services Division and is considered medically necessary when **all** the following are met:
 - 1.1 Must be ordered by a board certified gastroenterologist experienced in the treatment of inflammatory bowel disease; **AND**
 - 1.2 Documentation is provided that indicates the member has lost response to treatment and therapeutic drug monitoring is medically necessary to guide adjustments to therapy.



Coverage of any medical intervention discussed in a WellFirst Health medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Committee/Source

Date(s)

Document

created:

Medical Policy Committee/Health Services Division

October 17, 2018

Revised:

Reviewed:

Effective: 01/01/2020